NRx Pharmaceuticals (NASDAQ:NRXP) Given New $43.00 Price Target at Ascendiant Capital Markets

NRx Pharmaceuticals (NASDAQ:NRXPFree Report) had its price target decreased by Ascendiant Capital Markets from $50.00 to $43.00 in a report published on Friday, Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

NRx Pharmaceuticals Stock Down 5.6 %

Shares of NRx Pharmaceuticals stock opened at $3.21 on Friday. NRx Pharmaceuticals has a 12-month low of $1.90 and a 12-month high of $7.33. The company has a market capitalization of $34.35 million, a price-to-earnings ratio of -1.02 and a beta of 1.29. The firm’s 50-day moving average price is $5.57 and its two-hundred day moving average price is $30.02.

NRx Pharmaceuticals (NASDAQ:NRXPGet Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that NRx Pharmaceuticals will post -4 earnings per share for the current year.

Institutional Trading of NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. One Wealth Management Investment & Advisory Services LLC purchased a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXPFree Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 140,402 shares of the company’s stock, valued at approximately $65,000. One Wealth Management Investment & Advisory Services LLC owned approximately 0.16% of NRx Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

Featured Articles

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.